Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:09
05/14/21
05/14
09:09
05/14/21
09:09
VVNT

Vivint Smart Home

$11.75 /

+0.6 (+5.38%)

, SNOW

Snowflake

$188.13 /

-3.12 (-1.63%)

, PLUG

Plug Power

$21.96 /

-0.27 (-1.21%)

, ITRM

Iterum Therapeutics

/

+

, FREE

Whole Earth Brands

$12.76 /

-0.31 (-2.37%)

, SLDB

Solid Biosciences

$4.43 /

-0.18 (-3.90%)

, DASH

DoorDash

$116.22 /

+3.24 (+2.87%)

, COIN

Coinbase

$265.00 /

-18.6 (-6.56%)

, BPTH

Bio-Path

$5.16 /

-0.23 (-4.27%)

, DIS

Disney

$178.11 /

+0.26 (+0.15%)

, CRMD

CorMedix

$7.61 /

-0.26 (-3.30%)

, PTE

PolarityTE

$1.21 /

-0.02 (-1.63%)

, MKGI

Monaker Group

$2.94 /

-0.01 (-0.34%)

Check out this morning's…

ShowHide Related Items >><<
VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

ITRM Iterum Therapeutics
/

+

FREE Whole Earth Brands
$12.76 /

-0.31 (-2.37%)

SLDB Solid Biosciences
$4.43 /

-0.18 (-3.90%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

BPTH Bio-Path
$5.16 /

-0.23 (-4.27%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

MKGI Monaker Group
$2.94 /

-0.01 (-0.34%)

VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

07:09 Today Goldman Sachs
Vivint Smart Home upgraded to Buy from Neutral at Goldman Sachs
03/11/21 Deutsche Bank
Vivint upgraded to Buy on long-term opportunities at Deutsche Bank
03/11/21 Deutsche Bank
Vivint Smart Home upgraded to Buy from Hold at Deutsche Bank
02/25/21 Deutsche Bank
Vivint Smart Home price target lowered to $21 from $24 at Deutsche Bank
SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

04:55 Today Goldman Sachs
Snowflake upgraded to Buy from Neutral at Goldman Sachs
05/13/21 Mizuho
Snowflake price target lowered to $300 from $350 at Mizuho
05/03/21 Needham
Snowflake initiated with a Hold at Needham
05/03/21 Needham
Snowflake initiated with a Hold at Needham
PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

04/19/21 Evercore ISI
Plug Power initiated with an Outperform at Evercore ISI
04/19/21 Wells Fargo
Plug Power initiated with an Equal Weight at Wells Fargo
04/12/21 Morgan Stanley
Plug Power resumed at Equal Weight from Overweight at Morgan Stanley
04/12/21 Morgan Stanley
Plug Power downgraded to Equal Weight from Overweight at Morgan Stanley
ITRM Iterum Therapeutics
/

+

03/15/21 H.C. Wainwright
Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
12/24/20 H.C. Wainwright
Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
06/16/20 H.C. Wainwright
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/02/20 RBC Capital
Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
FREE Whole Earth Brands
$12.76 /

-0.31 (-2.37%)

02/22/21 Lake Street
Whole Earth Brands initiated with a Buy at Lake Street
02/12/21 Jefferies
Whole Earth Brands initiated with a Buy at Jefferies
01/28/21
Fly Intel: Top five analyst initiations
01/28/21 Roth Capital
Whole Earth Brands initiated with a Buy at Roth Capital
SLDB Solid Biosciences
$4.43 /

-0.18 (-3.90%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
DASH DoorDash
$116.22 /

+3.24 (+2.87%)

07:32 Today Wells Fargo
DoorDash upgraded to Overweight from Equal Weight at Wells Fargo
07:23 Today Wells Fargo
DoorDash upgraded to Overweight from Equal Weight at Wells Fargo
07:17 Today Truist
DoorDash upgraded to Buy from Hold at Truist
06:56 Today Truist
DoorDash upgraded to Buy from Hold at Truist
COIN Coinbase
$265.00 /

-18.6 (-6.56%)

06:49 Today Mizuho
Mizuho expects 'muted' stock reaction to 'strong' Coinbase results
06:03 Today Piper Sandler
Coinbase initiated with an Overweight at Piper Sandler
05/13/21 BTIG
BTIG sees Binance news as 'net positive' for Coinbase
05/13/21
Fly Intel: Top five analyst initiations
BPTH Bio-Path
$5.16 /

-0.23 (-4.27%)

04/06/21 H.C. Wainwright
Bio-Path price target raised to $12 from $10 at H.C. Wainwright
04/05/21 Roth Capital
Bio-Path triple regimen data 'highly favorable,' says Roth Capital
03/11/21 Roth Capital
Bio-Path Holdings initiated with a Buy at Roth Capital
11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
DIS Disney
$178.11 /

+0.26 (+0.15%)

08:13 Today Evercore ISI
Evercore doesn't see much in Disney Q2 report to materially change view
07:29 Today Morgan Stanley
Morgan Stanley 'not surprised' by Disney+ sub growth or commentary
07:13 Today Goldman Sachs
Disney price target lowered to $215 from $225 at Goldman Sachs
06:57 Today Citi
Disney shares to trade down on moderated sub outlook, says Citi
CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

04/14/21 JMP Securities
JMP 'confident' CorMedix has clear CRL resolution path with FDA
03/31/21 Truist
CorMedix price target lowered to $27 from $30 at Truist
03/02/21 B. Riley Securities
CorMedix price target lowered to $13.50 from $25 at B. Riley Securities
02/17/21 Needham
CorMedix initiated with a Buy at Needham
PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

11/19/20 Cantor Fitzgerald
PolarityTE patent status change removes key overhang, says Cantor Fitzgerald
MKGI Monaker Group
$2.94 /

-0.01 (-0.34%)

VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

ITRM Iterum Therapeutics
/

+

FREE Whole Earth Brands
$12.76 /

-0.31 (-2.37%)

SLDB Solid Biosciences
$4.43 /

-0.18 (-3.90%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

BPTH Bio-Path
$5.16 /

-0.23 (-4.27%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

  • 14
    May
  • 14
    Apr
  • 19
    Mar
  • 16
    Mar
  • 16
    Feb
  • 27
    Jan
  • 29
    Dec
  • 09
    Dec
  • 17
    Nov
  • 16
    Sep
  • 12
    Aug
  • 28
    Jul
PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

ITRM Iterum Therapeutics
/

+

SLDB Solid Biosciences
$4.43 /

-0.18 (-3.90%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

SNOW Snowflake
$188.13 /

-3.12 (-1.63%)

PLUG Plug Power
$21.96 /

-0.27 (-1.21%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

COIN Coinbase
$265.00 /

-18.6 (-6.56%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

Recommendations
TCR2 Therapeutics price target lowered to $45 from $57 at Wedbush » 07:27
05/14/21
05/14
07:27
05/14/21
07:27
TCRR

TCR2 Therapeutics

$19.05 /

-0.31 (-1.60%)

Wedbush analyst David…

Wedbush analyst David Nierengarten lowered the firm's price target on TCR2 Therapeutics to $45 from $57 and keeps an Outperform rating on the shares. The company reaffirmed that it is on track todetermine a recommended Phase 2 dose of gavo-cel for treatment-refractory mesothelin-expressing solid tumors and expects to initiate its Phase 1/2 expansion trial this year, Nierengarten tells investors in a research note. The analyst expects continued updates from treated patients over the rest of the year.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

  • 20
    Jan
  • 29
    Jul
Yesterday
On The Fly
Fly Intel: After-Hours Movers » 18:21
05/13/21
05/13
18:21
05/13/21
18:21
DMTK

DermTech

$29.25 /

-1.63 (-5.28%)

, HYRE

HyreCar

$8.92 /

-0.71 (-7.37%)

, DASH

DoorDash

$116.22 /

+3.24 (+2.87%)

, SWIR

Sierra Wireless

$13.55 /

+0.14 (+1.04%)

, PHAS

PhaseBio

$2.81 /

-0.11 (-3.77%)

, VVNT

Vivint Smart Home

$11.75 /

+0.6 (+5.38%)

, ABNB

Airbnb

$135.95 /

-4.22 (-3.01%)

, FSR

Fisker

$9.96 /

-0.32 (-3.11%)

, CRMD

CorMedix

$7.61 /

-0.26 (-3.30%)

, PTE

PolarityTE

$1.21 /

-0.02 (-1.63%)

, ACB

Aurora Cannabis

$7.33 /

-0.38 (-4.93%)

, ABCL

AbCellera

$34.80 /

+4.03 (+13.10%)

, AEYE

AudioEye

$18.04 /

-0.04 (-0.22%)

, EMKR

Emcore

$7.27 /

+0.21 (+2.97%)

, DIS

Disney

$178.11 /

+0.26 (+0.15%)

, NEWR

New Relic

$56.57 /

-0.325 (-0.57%)

, ALTG

Alta Equipment Group

$12.87 /

-0.13 (-1.00%)

, GDRX

GoodRx

$28.34 /

-1.14 (-3.87%)

, METX

Meten Edtechx

$1.29 /

-0.09 (-6.52%)

Check out this evening's…

ShowHide Related Items >><<
VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

SWIR Sierra Wireless
$13.55 /

+0.14 (+1.04%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

PHAS PhaseBio
$2.81 /

-0.11 (-3.77%)

NEWR New Relic
$56.57 /

-0.325 (-0.57%)

HYRE HyreCar
$8.92 /

-0.71 (-7.37%)

GDRX GoodRx
$28.34 /

-1.14 (-3.87%)

FSR Fisker
$9.96 /

-0.32 (-3.11%)

EMKR Emcore
$7.27 /

+0.21 (+2.97%)

DMTK DermTech
$29.25 /

-1.63 (-5.28%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

ALTG Alta Equipment Group
$12.87 /

-0.13 (-1.00%)

AEYE AudioEye
$18.04 /

-0.04 (-0.22%)

ACB Aurora Cannabis
$7.33 /

-0.38 (-4.93%)

ABNB Airbnb
$135.95 /

-4.22 (-3.01%)

ABCL AbCellera
$34.80 /

+4.03 (+13.10%)

DMTK DermTech
$29.25 /

-1.63 (-5.28%)

05/03/21
Fly Intel: Top five analyst initiations
05/03/21 BTIG
DermTech initiated with a Buy at BTIG
04/28/21 Lake Street
DermTech study with Stanford can provide added validation, says Lake Street
04/28/21 Craig-Hallum
DermTech stuck in Cigna 'reimbursement limbo,' says Craig-Hallum
HYRE HyreCar
$8.92 /

-0.71 (-7.37%)

02/05/21 Lake Street
HyreCar price target raised to $19 from $7 at Lake Street
01/29/21 Maxim
HyreCar price target raised to $18 from $7 at Maxim
01/29/21 Ladenburg
'Emerging leader' HyreCar upgraded to Buy with $17 target at Ladenburg
01/29/21 Ladenburg
HyreCar upgraded to Buy from Neutral at Ladenburg
DASH DoorDash
$116.22 /

+3.24 (+2.87%)

05/05/21 Cowen
Department of Labor comments incrementally encouraging for Uber/Lyft, says Cowen
04/26/21 Needham
DoorDash initiated with a Buy at Needham
04/23/21 JPMorgan
Olo agreement with DoorDash removes litigation risk, says JPMorgan
04/05/21 Evercore ISI
DoorDash initiated with an In Line at Evercore ISI
SWIR Sierra Wireless
$13.55 /

+0.14 (+1.04%)

03/23/21 Roth Capital
Roth believes IoT Services continued as ransomware impacted Sierra production
02/24/21 BMO Capital
Sierra Wireless price target raised to $19 from $13 at BMO Capital
02/16/21 RBC Capital
Sierra Wireless price target raised to $20 from $13 at RBC Capital
02/16/21 RBC Capital
Sierra Wireless price target raised to $20 from $13 at RBC Capital
PHAS PhaseBio
$2.81 /

-0.11 (-3.77%)

03/16/21 Needham
PhaseBio price target raised to Street high $19 at Needham
08/25/20 Citi
PhaseBio price target lowered to $10 from $12 at Citi
07/10/20 Stifel
PhaseBio transferred with Buy rating, $11 target at Stifel
05/29/20 Citi
PhaseBio price target raised to $12 from $11 at Citi
VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

03/11/21 Deutsche Bank
Vivint upgraded to Buy on long-term opportunities at Deutsche Bank
03/11/21 Deutsche Bank
Vivint Smart Home upgraded to Buy from Hold at Deutsche Bank
02/25/21 Deutsche Bank
Vivint Smart Home price target lowered to $21 from $24 at Deutsche Bank
01/15/21 Deutsche Bank
Vivint Smart Home downgraded to Hold on valuation at Deutsche Bank
ABNB Airbnb
$135.95 /

-4.22 (-3.01%)

04/26/21 Needham
Airbnb initiated with a Buy at Needham
04/05/21 Evercore ISI
Airbnb initiated with an Outperform at Evercore ISI
03/31/21 Wolfe Research
Airbnb assumed with a Peer Perform at Wolfe Research
03/10/21 Citi
Airbnb resumed with a Neutral at Citi
FSR Fisker
$9.96 /

-0.32 (-3.11%)

04/22/21
Fly Intel: Top five analyst downgrades
04/22/21 Goldman Sachs
Fisker downgraded to Sell from Neutral at Goldman Sachs
04/20/21 Morgan Stanley
Fisker remains 'top ranked' EV related SPAC startup, says Morgan Stanley
04/20/21 BofA
Fisker initiated with a Buy at BofA
CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

04/14/21 JMP Securities
JMP 'confident' CorMedix has clear CRL resolution path with FDA
03/31/21 Truist
CorMedix price target lowered to $27 from $30 at Truist
03/02/21 B. Riley
CorMedix price target lowered to $13.50 from $25 at B. Riley Securities
02/17/21 Needham
CorMedix initiated with a Buy at Needham
PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

11/19/20 Cantor Fitzgerald
PolarityTE patent status change removes key overhang, says Cantor Fitzgerald
ACB Aurora Cannabis
$7.33 /

-0.38 (-4.93%)

05/11/21 CIBC
Aurora Cannabis downgraded to Underperformer from Neutral at CIBC
04/28/21 BofA
Aurora Cannabis reinstated with a Neutral at BofA
04/28/21 BofA
Tilray reinstated with a Buy at BofA
04/05/21 CIBC
Aurora Cannabis price target lowered to C$15 from C$18.50 at CIBC
ABCL AbCellera
$34.80 /

+4.03 (+13.10%)

03/30/21 SVB Leerink
AbCellera price target lowered to $45 from $52 at SVB Leerink
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
01/26/21 Berenberg
Eli Lilly data 'incrementally positive' for AbCellera, says Berenberg
AEYE AudioEye
$18.04 /

-0.04 (-0.22%)

03/02/21 Maxim
AudioEye price target raised to $42 from $36 at Maxim
02/08/21 Maxim
AudioEye initiated with a Buy at Maxim
01/08/21 B. Riley
AudioEye price target raised to $32 from $25 at B. Riley Securities
09/01/20 B. Riley
AudioEye price target raised to $25 from $21 at B. Riley FBR
EMKR Emcore
$7.27 /

+0.21 (+2.97%)

03/04/21
Fly Intel: Top five analyst initiations
03/04/21 Craig-Hallum
Craig-Hallum bullish on Emcore, initiates with a Buy
03/04/21 Craig-Hallum
Emcore initiated with a Buy at Craig-Hallum
10/26/20 Northland
Northland upgrades Applied Optoelectronics to Market Perform on cable outlook
DIS Disney
$178.11 /

+0.26 (+0.15%)

05/12/21 Morgan Stanley
Disney price target raised to $210 from $200 at Morgan Stanley
05/10/21 Evercore ISI
American Campus upgraded to Outperform at Evercore ISI on faster Disney ramp
05/03/21 BofA
BofA adds Disney and Avalara, removes Comcast and Netflix from U.S. 1 List
04/26/21 Truist
Disney could be beneficiary if Roku stops carrying YouTube TV, says Truist
NEWR New Relic
$56.57 /

-0.325 (-0.57%)

02/05/21
Fly Intel: Top five analyst downgrades
02/05/21 Raymond James
New Relic downgraded to Market Perform from Strong Buy at Raymond James
02/05/21 Loop Capital
New Relic price target raised to $70 from $60 at Loop Capital
02/05/21 BMO Capital
New Relic price target raised to $71 from $64 at BMO Capital
ALTG Alta Equipment Group
$12.87 /

-0.13 (-1.00%)

03/22/21 DA Davidson
Alta Equipment Group price target raised to $16 from $14 at DA Davidson
03/19/21 B. Riley
Alta Equipment Group price target raised to $17 from $16 at B. Riley
03/11/21 DA Davidson
Alta Equipment Group initiated with a Buy at DA Davidson
01/07/21 B. Riley
Alta Equipment Group price target raised to $16 from $15 at B. Riley Securities
GDRX GoodRx
$28.34 /

-1.14 (-3.87%)

05/12/21 SVB Leerink
GoodRx moat still intact as Amazon Pharmacy push continues, says SVB Leerink
05/10/21 Cowen
GoodRx price target lowered to $58 from $70 at Cowen
04/05/21 Evercore ISI
GoodRx assumed with an Outperform at Evercore ISI
03/12/21 Barclays
GoodRx price target raised to $43 from $35 at Barclays
METX Meten Edtechx
$1.29 /

-0.09 (-6.52%)

VVNT Vivint Smart Home
$11.75 /

+0.6 (+5.38%)

SWIR Sierra Wireless
$13.55 /

+0.14 (+1.04%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

PHAS PhaseBio
$2.81 /

-0.11 (-3.77%)

NEWR New Relic
$56.57 /

-0.325 (-0.57%)

HYRE HyreCar
$8.92 /

-0.71 (-7.37%)

GDRX GoodRx
$28.34 /

-1.14 (-3.87%)

FSR Fisker
$9.96 /

-0.32 (-3.11%)

EMKR Emcore
$7.27 /

+0.21 (+2.97%)

DMTK DermTech
$29.25 /

-1.63 (-5.28%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

ALTG Alta Equipment Group
$12.87 /

-0.13 (-1.00%)

AEYE AudioEye
$18.04 /

-0.04 (-0.22%)

ACB Aurora Cannabis
$7.33 /

-0.38 (-4.93%)

ABNB Airbnb
$135.95 /

-4.22 (-3.01%)

ABCL AbCellera
$34.80 /

+4.03 (+13.10%)

  • 18
    Mar
  • 11
    Feb
  • 04
    Feb
  • 22
    Jan
  • 07
    Jan
  • 11
    Dec
  • 10
    Dec
  • 09
    Dec
  • 11
    Nov
  • 23
    Sep
  • 27
    Aug
  • 28
    Jul
GDRX GoodRx
$28.34 /

-1.14 (-3.87%)

FSR Fisker
$9.96 /

-0.32 (-3.11%)

DMTK DermTech
$29.25 /

-1.63 (-5.28%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

ACB Aurora Cannabis
$7.33 /

-0.38 (-4.93%)

ABNB Airbnb
$135.95 /

-4.22 (-3.01%)

SWIR Sierra Wireless
$13.55 /

+0.14 (+1.04%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

NEWR New Relic
$56.57 /

-0.325 (-0.57%)

HYRE HyreCar
$8.92 /

-0.71 (-7.37%)

GDRX GoodRx
$28.34 /

-1.14 (-3.87%)

FSR Fisker
$9.96 /

-0.32 (-3.11%)

DMTK DermTech
$29.25 /

-1.63 (-5.28%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

ACB Aurora Cannabis
$7.33 /

-0.38 (-4.93%)

ABNB Airbnb
$135.95 /

-4.22 (-3.01%)

ABCL AbCellera
$34.80 /

+4.03 (+13.10%)

PTE PolarityTE
$1.21 /

-0.02 (-1.63%)

GDRX GoodRx
$28.34 /

-1.14 (-3.87%)

FSR Fisker
$9.96 /

-0.32 (-3.11%)

EMKR Emcore
$7.27 /

+0.21 (+2.97%)

DMTK DermTech
$29.25 /

-1.63 (-5.28%)

DIS Disney
$178.11 /

+0.26 (+0.15%)

DASH DoorDash
$116.22 /

+3.24 (+2.87%)

ACB Aurora Cannabis
$7.33 /

-0.38 (-4.93%)

ABNB Airbnb
$135.95 /

-4.22 (-3.01%)

ABCL AbCellera
$34.80 /

+4.03 (+13.10%)

Earnings
CorMedix reports Q1 EPS (20c), consensus (18c) » 16:43
05/13/21
05/13
16:43
05/13/21
16:43
CRMD

CorMedix

$7.61 /

-0.26 (-3.30%)

The Company reported cash…

The Company reported cash and short-term investments of $81.2 million at March 31, 2021, excluding restricted cash. The Company believes that, based on its current cash resources, it has sufficient resources to fund operations at least into the second half of 2022. approximately $1.3 million in net proceeds. Closing is anticipated in 2Q of 2021. Khoso Baluch, CorMedix CEO commented, "As we continue to work through the items required by FDA for resubmission of the NDA, we remain confident in our efforts to bring DefenCath to hemodialysis patients as an important novel antimicrobial catheter lock solution to reduce catheter related blood stream infections in patients receiving hemodialysis via central venous catheters. We believe we have the right team and resources to accomplish this as we advance DefenCath through the regulatory approval process."

ShowHide Related Items >><<
CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

04/14/21 JMP Securities
JMP 'confident' CorMedix has clear CRL resolution path with FDA
03/31/21 Truist
CorMedix price target lowered to $27 from $30 at Truist
03/02/21 B. Riley
CorMedix price target lowered to $13.50 from $25 at B. Riley Securities
02/17/21 Needham
CorMedix initiated with a Buy at Needham
CRMD CorMedix
$7.61 /

-0.26 (-3.30%)

  • 28
    Jul
Earnings
Bolt Biotherapeutics reports Q1 EPS ($1.14), consensus (60c) » 16:39
05/13/21
05/13
16:39
05/13/21
16:39
BOLT

Bolt Biotherapeutics

$18.24 /

-1.15 (-5.93%)

Cash, cash equivalents,…

Cash, cash equivalents, and marketable securities were $302.9 million as of March 31, 2021, which is expected to fund operations into 2023 - Bolt is well positioned to continue to drive growth across the company and advance the pipeline through key milestones, with cash to fund operations into 2023. "Our successful IPO in the first quarter of 2021 places us in a position of strength to deliver on value-creating milestones in 2021 and 2022. We continue to advance our Phase 1/2 trial for our lead candidate, BDC-1001, for the treatment of patients with HER2-expressing solid tumors. We look forward to completing the monotherapy dose escalation and initiating the monotherapy Phase 2 dose expansion cohorts as well as the evaluation of combining BDC-1001 with an anti-PD-1 antibody later in 2021," said Randall C. Schatzman, Ph.D., Chief Executive Officer of Bolt. "Beyond BDC-1001, we continue to advance our pipeline and are on track to initiate clinical trials for CEA-targeted ISAC BDC-2034 in 2022 and we expect to designate our third clinical candidate later this year."

ShowHide Related Items >><<
BOLT Bolt Biotherapeutics
$18.24 /

-1.15 (-5.93%)

BOLT Bolt Biotherapeutics
$18.24 /

-1.15 (-5.93%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
03/02/21 Morgan Stanley
Bolt Biotherapeutics initiated with an Overweight at Morgan Stanley
03/02/21 Stifel
Bolt Biotherapeutics initiated with a Buy at Stifel
BOLT Bolt Biotherapeutics
$18.24 /

-1.15 (-5.93%)

  • 05
    Feb
BOLT Bolt Biotherapeutics
$18.24 /

-1.15 (-5.93%)

Hot Stocks
CorMedix appoints Thomas Nusbickel as Chief Commercial Officer » 08:32
05/13/21
05/13
08:32
05/13/21
08:32
CRMD

CorMedix

$7.87 /

-0.33 (-4.02%)

, CHRS

Coherus Biosciences

$13.85 /

-0.23 (-1.63%)

CorMedix (CRMD) announced…

CorMedix (CRMD) announced the appointment of Thomas Nusbickel to the newly created position of Chief Commercial Officer. Tom will be responsible for advancing the commercial strategy needed to bring DefenCath to patients in the U.S. when approved by FDA for commercial distribution. Tom most recently served as Vice President of Market Access and Government Affairs at Coherus Biosciences (CHRS).

ShowHide Related Items >><<
CRMD CorMedix
$7.87 /

-0.33 (-4.02%)

CHRS Coherus Biosciences
$13.85 /

-0.23 (-1.63%)

CRMD CorMedix
$7.87 /

-0.33 (-4.02%)

04/14/21 JMP Securities
JMP 'confident' CorMedix has clear CRL resolution path with FDA
03/31/21 Truist
CorMedix price target lowered to $27 from $30 at Truist
03/02/21 B. Riley
CorMedix price target lowered to $13.50 from $25 at B. Riley Securities
02/17/21 Needham
CorMedix initiated with a Buy at Needham
CHRS Coherus Biosciences
$13.85 /

-0.23 (-1.63%)

05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
02/25/21 H.C. Wainwright
Coherus Biosciences price target lowered to $29 from $33 at H.C. Wainwright
11/19/20 Mizuho
Coherus Biosciences price target lowered to $30 from $35 at Mizuho
CRMD CorMedix
$7.87 /

-0.33 (-4.02%)

CHRS Coherus Biosciences
$13.85 /

-0.23 (-1.63%)

  • 28
    Jul
Earnings
Frequency Therapeutics reports Q1 EPS (60c), consensus (28c) » 07:41
05/13/21
05/13
07:41
05/13/21
07:41
FREQ

Frequency Therapeutics

$10.11 /

-0.31 (-2.98%)

Reports Q1 revenue…

Reports Q1 revenue $4.65M, consensus $8.13M. "As we work to develop a novel medicine for the treatment of the most common form of hearing loss, our initial focus has been to investigate the broadest set of potential conditions and severities through a comprehensive series of probing studies. With data from all of our single administration studies, we have been able to better define the groups of patients that we believe are responding to FX-322, while also informing the optimal study design for new placebo-controlled Phase 2 trials," said David Lucchino, Frequency's CEO.

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$10.11 /

-0.31 (-2.98%)

FREQ Frequency Therapeutics
$10.11 /

-0.31 (-2.98%)

03/24/21 B. Riley
Frequency Therapeutics price target lowered to $35 from $79 at B. Riley
03/24/21 Oppenheimer
Frequency Therapeutics price target lowered to $20 from $68 at Oppenheimer
02/11/21 Oppenheimer
Frequency Therapeutics price target raised to $68 from $48 at Oppenheimer
01/27/21
Fly Intel: Top five analyst upgrades
FREQ Frequency Therapeutics
$10.11 /

-0.31 (-2.98%)

FREQ Frequency Therapeutics
$10.11 /

-0.31 (-2.98%)

Hot Stocks
Akouos expects cash to fund operations for at least next two years » 07:18
05/13/21
05/13
07:18
05/13/21
07:18
AKUS

Akouos

$12.43 /

-0.72 (-5.48%)

Cash, cash equivalents,…

Cash, cash equivalents, and marketable securities were $286.6 million as of March 31, 2021, as compared to $308.0 million as of December 31, 2020. Akouos expects its cash balance to fund operations for at least the next two years.

ShowHide Related Items >><<
AKUS Akouos
$12.43 /

-0.72 (-5.48%)

AKUS Akouos
$12.43 /

-0.72 (-5.48%)

04/28/21 Piper Sandler
Akouos transferred with Overweight, $40 target at Piper Sandler
04/27/21 H.C. Wainwright
Akouos initiated with a Buy at H.C. Wainwright
04/05/21
Akouos management to meet virtually with BTIG
03/30/21 BofA
Akouos downgraded to Neutral at BofA on OTOF IND filing delay
AKUS Akouos
$12.43 /

-0.72 (-5.48%)

  • 26
    Jun
Earnings
Akouos reports Q1 EPS (47c), consensus (38c) » 07:18
05/13/21
05/13
07:18
05/13/21
07:18
AKUS

Akouos

$12.43 /

-0.72 (-5.48%)

"We continue to…

"We continue to demonstrate our leadership in the field of inner ear genetic medicines. Recently, FDA granted AK-OTOF, our lead product candidate, what we believe are the first Orphan Drug and Rare Pediatric Disease designations for a genetic form of hearing loss. At the ASGCT Annual Meeting, our team presented nonclinical data demonstrating the unique applicability of our genetic medicine platform to potentially restore, improve, and preserve physiologic hearing for a monogenic condition and a condition of complex etiology," said Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos. "These accomplishments have been made possible by our team of leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy, including the recent addition of Dr. Kathy Reape as chief development officer. We continue to build our team's capabilities, infrastructure, and facilities to support our planned IND submissions for AK-OTOF and AK-antiVEGF in 2022, and are progressing our earlier stage programs towards candidate selection or target announcement."

ShowHide Related Items >><<
AKUS Akouos
$12.43 /

-0.72 (-5.48%)

AKUS Akouos
$12.43 /

-0.72 (-5.48%)

04/28/21 Piper Sandler
Akouos transferred with Overweight, $40 target at Piper Sandler
04/27/21 H.C. Wainwright
Akouos initiated with a Buy at H.C. Wainwright
04/05/21
Akouos management to meet virtually with BTIG
03/30/21 BofA
Akouos downgraded to Neutral at BofA on OTOF IND filing delay
AKUS Akouos
$12.43 /

-0.72 (-5.48%)

  • 26
    Jun
Earnings
Liquidia Technologies reports Q1 EPS (21c), consensus (21c) » 07:11
05/13/21
05/13
07:11
05/13/21
07:11
LQDA

Liquidia Technologies

$2.75 /

-0.085 (-3.00%)

Reports Q1 revenue…

Reports Q1 revenue $3.08M, consensus $870,000. Damian deGoa, Liquidia's CEO, said: "This first quarter has been an important time of transition and re-structuring for the company as it strengthens its position and commitment to the products and patients that we support. We believe that our renewed focus and financial discipline are essential in order for the company to achieve its objectives in 2021 and beyond."

ShowHide Related Items >><<
LQDA Liquidia Technologies
$2.75 /

-0.085 (-3.00%)

LQDA Liquidia Technologies
$2.75 /

-0.085 (-3.00%)

12/04/20
Fly Intel: Top five analyst initiations
12/04/20 H.C. Wainwright
Liquidia Technologies initiated with a Buy at H.C. Wainwright
11/20/20
Fly Intel: Top five analyst downgrades
11/20/20 Wedbush
Liquidia Technologies downgraded to Neutral from Outperform at Wedbush
LQDA Liquidia Technologies
$2.75 /

-0.085 (-3.00%)

  • 30
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.